X0306 4 2013-04-11 0 0001477598 Omthera Pharmaceuticals, Inc. OMTH 0001237289 SANDELL SCOTT D 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 0 0 1 0 Warrant (right to buy) .01 2013-04-11 4 A 0 156250 0 A 2013-04-16 2023-02-15 Common Stock 156250 156250 I See Note 2 Secured Convertible Promissory Note 8 2013-04-11 4 A 0 633219 A 2013-04-16 2014-02-15 Common Stock 633219 633219 I See Note 2 Upon the closing of the Issuer's initial public offering ("IPO"), the warrant will automatically convert into the number of shares of Common Stock shown in column 5 less the number of shares equal to the payment of the exercise price. The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, L.P. ("NEA Partners 13"). NEA Partners 13 is the sole general partner of New Enterprise Associates 13, L.P. ("NEA 13"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the securities held by NEA 13, except to the extent of his pecuniary interest therein. Upon the closing of the Issuer's IPO, the Secured Convertible Promissory Note will convert into the number of shares of Common Stock shown in column 5. The Secured Convertible Promissory Note was issued to NEA 13 in exchange for $5,000,000. This is the maturity date of the Secured Convertible Promissory Note. /s/ Louis Citron, attorney-in-fact 2013-04-11